glp-1/gip/glucagon triple agonist New strategies for the treatment of obesity and metabolic dysfunctions Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide

Journal of Translational Medicine

Unexpected cardiovascular risks of glucagon-like peptide-1 receptor agonist and aspirin co-administration in individuals with obesity, with and without type 2 diabetes: a propensity score matched cohort study

Of particular interest to researchers is Retatrutides triple agonist mechanism, which published Phase 2 data suggests produces distinct and potentially additive metabolic effects compared to both selective GLP-1 agonists and dual GIP/GLP-1 agonists

thank you so much for reading and supporting this newsletter

Irfan Khan, MD , offers expert guidance on how Tirzepatide can help patients achieve their weight loss and metabolic health goals

N Engl J Med 2008;359:1577-89